title: Depressor and Anti-Inflammatory Effects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study).
abstract: BACKGROUND
  We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective, randomized clinical trial.
  
  
  METHODS
  Forty-four hypertensive patients who had coronary artery disease (CAD) were enrolled. We randomly assigned patients to changeover from their prior angiotensin II receptor blockers (ARBs) to either azilsartan or olmesartan, and followed the patients for 12 weeks.
  
  
  RESULTS
  Office systolic blood pressure (SBP) in the azilsartan group was significantly decreased after 12 weeks. SBP and diastolic blood pressure (DBP) after 12 weeks in the azilsartan group were significantly lower than those in the olmesartan group. The percentage of patients who reached the target BP at 12 weeks (78%) in the azilsartan group was significantly higher than that at 12 weeks (45%) in the olmesartan group. There were no significant changes in pentraxin-3, high-sensitively C-reactive protein or adiponectin in blood after 12 weeks in either group. Although serum levels of creatinine (Cr) in the azilsartan group significantly increased, these changes were within the respective normal range.
  
  
  CONCLUSIONS
  In conclusion, the ability of azilsartan to reduce BP may be superior to that of prior ARBs with equivalent safety in hypertensive patients with CAD.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Sen
authors.initials: S
authors.lastname: Adachi
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan; Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Miura
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shiga
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arimura
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kuwano
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Kitajima
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Amane
authors.initials: A
authors.lastname: Ike
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugihara
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Iwata
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nishikawa
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Natsumi
authors.initials: N
authors.lastname: Morito
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan; Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
keywords: Angiotensin II type 1 receptor blocker; Blood pressure; Creatinine